Janus Henderson Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.51B Buy
6,931,036
+528,386
+8% +$117M 0.72% 19
2025
Q4
$1.46B Buy
6,402,650
+1,468,961
+30% +$335M 0.66% 21
2025
Q3
$1.14B Buy
4,933,689
+1,150,055
+30% +$234M 0.52% 37
2025
Q2
$702M Buy
3,783,634
+62,803
+2% +$11.7M 0.34% 63
2025
Q1
$764M Sell
3,720,831
-525,214
-12% -$102M 0.42% 43
2024
Q4
$755M Sell
4,246,045
-5,800,981
-58% -$1.07B 0.38% 49
2024
Q3
$1.98B Sell
10,047,026
-1,403,597
-12% -$262M 1.02% 13
2024
Q2
$1.96B Buy
11,450,623
+552,377
+5% +$91.5M 1.05% 11
2024
Q1
$1.98B Buy
10,898,246
+1,240,434
+13% +$214M 1.08% 10
2023
Q4
$1.5B Buy
9,657,812
+116,317
+1% +$17M 0.89% 15
2023
Q3
$1.42B Sell
9,541,495
-1,181,766
-11% -$173M 0.93% 12
2023
Q2
$1.44B Sell
10,723,261
-2,771,475
-21% -$406M 0.9% 14
2023
Q1
$2.15B Sell
13,494,736
-2,029,836
-13% -$310M 1.42% 8
2022
Q4
$2.51B Sell
15,524,572
-16,883,120
-52% -$2.59B 1.79% 5
2022
Q3
$4.35B Buy
32,407,692
+16,128,402
+99% +$2.31B 1.63% 7
2022
Q2
$2.49B Sell
16,279,290
-852,827
-5% -$130M 1.72% 7
2022
Q1
$2.78B Buy
17,132,117
+2,343,546
+16% +$340M 1.34% 8
2021
Q4
$2B Sell
14,788,571
-1,658,755
-10% -$196M 0.84% 11
2021
Q3
$1.77B Sell
16,447,326
-1,381,568
-8% -$158M 0.78% 15
2021
Q2
$2.01B Sell
17,828,894
-593,678
-3% -$66.9M 0.86% 13
2021
Q1
$1.99B Buy
18,422,572
+90,294
+0.5% +$9.66M 0.91% 11
2020
Q4
$1.96B Buy
18,332,278
+1,363,299
+8% +$131M 0.91% 11
2020
Q3
$1.49B Buy
16,968,979
+580,398
+4% +$54.6M 0.77% 20
2020
Q2
$1.61B Buy
16,388,581
+4,872,892
+42% +$429M 0.9% 15
2020
Q1
$877M Buy
11,515,689
+5,208,549
+83% +$444M 0.6% 27
2019
Q4
$558M Buy
6,307,140
+2,554,873
+68% +$212M 0.29% 85
2019
Q3
$284M Sell
3,752,267
-5,105,308
-58% -$350M 0.15% 159
2019
Q2
$644M Sell
8,857,575
-1,150,059
-11% -$90.4M 0.35% 64
2019
Q1
$807M Buy
10,007,634
+887,231
+10% +$72.6M 0.45% 45
2018
Q4
$841M Buy
9,120,403
+4,163,872
+84% +$366M 0.54% 27
2018
Q3
$469M Sell
4,956,531
-287,425
-5% -$27.3M 0.25% 104
2018
Q2
$486M Buy
5,243,956
+717,452
+16% +$70.1M 0.28% 91
2018
Q1
$428M Buy
4,526,504
+2,312,173
+104% +$254M 0.25% 107
2017
Q4
$214M Buy
2,214,331
+370,647
+20% +$34.9M 0.13% 198
2017
Q3
$164M Sell
1,843,684
-1,989,851
-52% -$151M 0.11% 242
2017
Q2
$278M Buy
3,833,535
+3,646,510
+1,950% +$245M 0.19% 144
2017
Q1
$12.2M Sell
187,025
-2,265
-1% -$142K 0.09% 255
2016
Q4
$11.9M Sell
189,290
-2,465
-1% -$150K 0.09% 257
2016
Q3
$12.1M Sell
191,755
-5,949
-3% -$385K 0.09% 258
2016
Q2
$12.2M Sell
197,704
-12,997
-6% -$792K 0.1% 246
2016
Q1
$12M Buy
210,701
+3,098
+1% +$173K 0.1% 235
2015
Q4
$12.3M Sell
207,603
-15,535
-7% -$895K 0.1% 231
2015
Q3
$12.1M Buy
223,138
+6,420
+3% +$418K 0.11% 219
2015
Q2
$14.6M Buy
216,718
+1,960
+0.9% +$128K 0.11% 215
2015
Q1
$12.6M Sell
214,758
-10,148
-5% -$613K 0.1% 240
2014
Q4
$14.7M Hold
224,906
0.11% 230
2014
Q3
$13M Sell
224,906
-21,849
-9% -$1.21M 0.12% 176
2014
Q2
$13.9M Buy
246,755
+10,342
+4% +$543K 0.13% 177
2014
Q1
$12.2M Buy
236,413
+19,488
+9% +$985K 0.12% 186
2013
Q4
$11.5M Buy
216,925
+7,974
+4% +$392K 0.12% 200
2013
Q3
$9.35M Sell
208,951
-890
-0.4% -$39.5K 0.1% 212
2013
Q2
$8.73M Buy
+209,841
New +$9.18M 0.1% 210

Other funds holding ABBV

Janus Henderson Group's ABBV Position: Q1 2026 in Review

Janus Henderson Group increased its AbbVie (ABBV) stake by 8.3% in Q1 2026, buying an estimated $117M and bringing the position to 6,931,036 shares worth $1.51B. The position accounts for 0.72% of the portfolio, ranked #19.

Janus Henderson Group first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.35B in Q3 2022. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Janus Henderson Group held 6,931,036 shares of AbbVie worth $1.51B as of Q1 2026.
  • Janus Henderson Group bought 528,386 AbbVie shares in Q1 2026, an estimated $117M.
  • AbbVie made up 0.72% of Janus Henderson Group's portfolio in Q1 2026, its #19 holding.
  • Janus Henderson Group first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Janus Henderson Group's AbbVie position peaked at $4.35B in Q3 2022.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.